Aptose Biosciences (APTO) 10-K 23 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 23, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Aptose Biosciences Inc.
Entity Central Index Key	0000882361
Trading Symbol	apto
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		88,885,238
Entity Public Float			$ 478,045,833
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Shares, no par value

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 117,393	$ 79,842
Investments	5,000	17,758
Prepaid expenses	2,554	1,025
Other current assets	129	141
Total current assets	125,076	98,766
Non-current assets:
Property and equipment	261	334
Right-of-use assets, operating leases	925	1,376
Total non-current assets	1,186	1,710
Total assets	126,262	100,476
Current liabilities:
Accounts payable	2,171	1,960
Accrued liabilities	4,102	3,058
Current portion of lease liability, operating leases	539	521
Total current liabilities	6,812	5,539
Non-current liabilities:
Lease liability, operating leases	535	1,011
Total liabilities	7,347	6,550
Shareholders’ equity:
Common shares, no par value, unlimited authorized shares, 88,881,737 and 76,108,031 shares issued and outstanding at December 31, 2020 and December 31, 2019	429,523	365,490
Additional paid-in capital	50,861	34,649
Accumulated other comprehensive loss	(4,316)	(4,298)
Deficit	(357,153)	(301,915)
Total shareholders’ equity	118,915	93,926
Total liabilities and shareholders’ equity	$ 126,262	$ 100,476

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Parentheticals) - $ / shares $ / shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Common shares, no par value (in dollars per share)	$ 0	$ 0
Common shares, issued (in shares)	88,881,737	76,108,031
Common shares, outstanding (in shares)	88,881,737	76,108,031

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue
Expenses:
Research and development	29,288	16,835
General and administrative	26,480	10,022
Operating expenses	55,768	26,857
Other income :
Interest income	522	574
Foreign exchange gain	8	6
Total other income	530	580
Net loss	(55,238)	(26,277)
Other comprehensive loss:
Unrealized gain/(loss) on securities available-for-sale	(18)	18
Total comprehensive loss	$ (55,256)	$ (26,259)
Basic and diluted loss per common share (in dollars per share)	$ (0.67)	$ (0.52)
Weighted average number of common shares outstanding used in the calculation of (in thousands)
Basic and diluted loss per common share (in shares)	81,837	50,160

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]AOCI Attributable to Parent [Member]	Public Offering [Member]Retained Earnings [Member]	Public Offering [Member]	December 2019 Public Offering [Member]Common Stock [Member]	December 2019 Public Offering [Member]Additional Paid-in Capital [Member]	December 2019 Public Offering [Member]AOCI Attributable to Parent [Member]	December 2019 Public Offering [Member]Retained Earnings [Member]	December 2019 Public Offering [Member]	June 2019 Public Offering [Member]Common Stock [Member]	June 2019 Public Offering [Member]Additional Paid-in Capital [Member]	June 2019 Public Offering [Member]AOCI Attributable to Parent [Member]	June 2019 Public Offering [Member]Retained Earnings [Member]	June 2019 Public Offering [Member]	The 2019 Share Purchase Agreement [Member]Common Stock [Member]	The 2019 Share Purchase Agreement [Member]Additional Paid-in Capital [Member]	The 2019 Share Purchase Agreement [Member]AOCI Attributable to Parent [Member]	The 2019 Share Purchase Agreement [Member]Retained Earnings [Member]	The 2019 Share Purchase Agreement [Member]	The 2018 ATM Offering [Member]Common Stock [Member]	The 2018 ATM Offering [Member]	The 2018 Purchase Agreement [Member]Common Stock [Member]	The 2018 Purchase Agreement [Member]Additional Paid-in Capital [Member]	The 2018 Purchase Agreement [Member]AOCI Attributable to Parent [Member]	The 2018 Purchase Agreement [Member]Retained Earnings [Member]	The 2018 Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018																												38,162,000
Balance at Dec. 31, 2018																												$ 261,072	$ 32,963	$ (4,316)	$ (275,638)	$ 14,081
Common shares issued (in shares)						18,544,000					11,500,000					1,971,000					77,000		5,502,000
Common shares issued						$ 68,588				$ 68,588	$ 19,594				$ 19,594	$ 4,730				$ 4,730	$ 178	$ 178	$ 10,000				$ 10,000
Common shares issued on redemption of restricted share units (in shares)																												40,000
Common shares issued on redemption of restricted share units																												$ 80	(80)
Common shares issued upon exercise of stock options (in shares)																												312,000				312,000
Common shares issued upon exercise of stock options																												$ 1,248	(530)			$ 718
Stock-based compensation																													2,296			2,296
Other comprehensive gain																														18		18
Net loss																															(26,277)	(26,277)
Balance (in shares) at Dec. 31, 2019																												76,108,000
Balance at Dec. 31, 2019																												$ 365,490	34,649	(4,298)	(301,915)	93,926
Common shares issued (in shares)	11,854,000																										5,502,433
Common shares issued	$ 58,234				$ 58,234
Common shares issued on redemption of restricted share units (in shares)																												685,000
Common shares issued on redemption of restricted share units																												$ 4,801	(4,801)
Common shares issued upon exercise of stock options (in shares)																												235,000				235,000
Common shares issued upon exercise of stock options																												$ 998	(425)			$ 573
Stock-based compensation																													21,438			21,438
Other comprehensive gain																														(18)		(18)
Net loss																															(55,238)	(55,238)
Balance (in shares) at Dec. 31, 2020																												88,882,000
Balance at Dec. 31, 2020																												$ 429,523	$ 50,861	$ (4,316)	$ (357,153)	$ 118,915

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (55,238)	$ (26,277)
Items not involving cash:
Stock-based compensation	21,438	2,296
Shares issued to Aspire Capital as commitment fees		360
Depreciation and amortization	152	152
Amortization of right-of-use assets	462	461
Interest on lease liabilities	69	90
Unrealized foreign exchange gain/(loss)	(8)	(23)
Accrued interest on investments	33	(34)
Change in operating working capital:
Prepaid expenses	(1,529)	(379)
Operating lease payments	(537)	(471)
Other assets	12	(40)
Accounts payable	211	645
Accrued liabilities	1,044	1,662
Cash used in operating activities	(33,891)	(21,558)
Cash flows from financing activities:
Offering costs paid	(168)	(437)
Issuance of common shares pursuant to exercise of stock options	573	718
Cash provided by financing activities	58,807	103,448
Cash flows from (used in) investing activities:
Maturity (acquisition) of investments, net	12,707	(17,268)
Purchase of property and equipment	(79)	(102)
Cash provided by (used in) investing activities	12,628	(17,370)
Effect of exchange rate fluctuations on cash and cash equivalents held	7	23
Increase in cash and cash equivalents	37,551	64,543
Cash and cash equivalents, beginning of year	79,842	15,299
Cash and cash equivalents, end of year	117,393	79,842
Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares	58,402
December 2019 Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares		68,883
June 2019 Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares		19,736
The 2018 ATM Offering [Member]
Cash flows from financing activities:
Issuance of common shares		178
The 2019 Share Purchase Agreement [Member]
Cash flows from financing activities:
Issuance of common shares		4,370
The 2018 Purchase Agreement [Member]
Cash flows from financing activities:
Issuance of common shares		$ 10,000

Note 1 - Reporting Entity

Note 1 - Reporting Entity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Reporting entity: Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's executive offices are located in San Diego, California and its head office is located in Toronto, Canada. Aptose has two second CG026806 806” 3 1, 806 1 June 2020, 253, second 1b We are advancing first not 19 not Since our inception, we have financed our operations and technology acquisitions primarily from equity financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, drug manufacturing costs, laboratory supplies and materials, and professional fees. We do not We believe that our cash, cash equivalents and investments on hand at December 31, 2020 12 twelve may Our ability to raise additional funds could be affected by adverse market conditions, the status of our product pipeline, possible delays in enrollment in our trial related to COVID- 19, may not may

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Significant accounting policies (a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation. (b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10 (c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected. (d) Leases Effective January 1, 2019, No. 2016 02, 842 twelve Impact of adoption: As a result of adopting Topic 842, January 1, 2019, $1.570 $1.647 $78 (e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90 (f) Investments: Investments consist of time deposits with original maturities greater than 90 (g) Concentration of risk: The Company is subject to credit risk from the Company's cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1 (h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight-line basis as follows: Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate. (i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed. The Company records expenses for research and development activities based on Management's estimates of services received and efforts expended pursuant to contracts with vendors that conduct research and development on Aptose's behalf. The financial terms vary from contract to contract and may (j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company's financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. (k) Stock-based compensation: The Company has a stock-based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company's Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company's stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non-employees are measured at grant-date fair value of the equity instruments issued in accordance with FASB issued accounting standards update No 2018 07, 718. The Company has a stock incentive plan pursuant to which the Board may (l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company's Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one (m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company's stock options and warrants in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share. (n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2020 December 31, 2019, not not

Note 3 - Cash and Cash Equivale

Note 3 - Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	3. Cash and cash equivalents: Cash and cash equivalents consist of cash of $329 December 31, 2019 $1.640 90 $117.064 December 31, 2019 - $78.202

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Prepaid Expenses [Text Block]	4. Prepaid expenses: December 31, December 31, 2020 2019 Prepaid research and development expenses $ 622 $ 451 Other prepaid expenses 1,932 574 $ 2,554 $ 1,025

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment: December 31, 2020 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 177 $ 8 Computer hardware 170 99 71 Computer software 222 174 48 Office furniture 140 72 68 Leasehold improvements 184 118 66 $ 901 $ 640 $ 261 December 31, 2019 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 160 $ 25 Computer hardware 122 60 62 Computer software 222 128 94 Office furniture 116 51 65 Leasehold improvements 177 89 88 $ 822 $ 488 $ 334

Note 6 - Right of-use Assets, O

Note 6 - Right of-use Assets, Operating Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Right-of-use Assets Disclosure [Text Block]	6. Right of-use assets, operating leases: Year ended December 31, 2020 Year ended Right-of-use assets, beginning of year $ 1,837 $ 1,570 Additions to right-of-use assets 11 267 Right-of-use assets, end of year 1,848 1,837 Accumulated amortization (923 ) (461 ) Right-of use assets, NBV 925 1,376

Note 7 - Investments

Note 7 - Investments	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	7. Investments: Investments consisted of the following as of December 31, 2020 December 31, 2019: December 31, 2020 Cost Unrealized gain/(loss) Market value United States Treasury Bills 5,000 - 5,000 5,000 - 5,000 December 31, 2019 Cost Unrealized gain Market value Guaranteed investment certificates, issued by a Canadian financial institution 12,008 18 12,026 Commercial notes 3,736 - 3,736 Canadian provincial promissory note 1,996 - 1,996 17,740 18 17,758

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements and Financial Instruments	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	8. Fair value measurements and financial instruments: The fair value hierarchy establishes three Level 1 Level 2 not Level 3 no The fair value hierarchy gives the highest priority to Level 1 3 The following table presents the Company's assets that are measured at fair value on a recurring basis for the periods presented: December 31, 2020 Level 1 Level 2 Level 3 Assets Money Market accounts $ 668 - $ 668 - Money Market Funds 44,000 - 44,000 - High interest savings accounts 48,397 $ - 48,397 - United States Treasury Bill 5,000 - 5,000 - Government of Canada Treasury Bill 23,999 - 23,999 - $ 122,064 $ - $ 122,064 $ - December 31, 2019 Level 1 Level 2 Level 3 Assets High interest savings account $ 2,989 $ - $ 2,989 - Commercial notes 6,235 - 6,235 - Canadian provincial promissory notes 5,493 - 5,493 - Guaranteed investment certificates, issued by a Canadian financial institution 81,243 - 81,243 - $ 95,960 $ - $ 95,960 $ -

Note 9 - Accrued Liabilities

Note 9 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. Accrued liabilities: Accrued liabilities as of December 31, 2020 December 31, 2019 December 31, December 31, 2020 2019 Accrued personnel related costs $ 1,917 $ 1,739 Accrued research and development expenses 1,932 1,062 Other accrued expenses 253 257 $ 4,102 $ 3,058

Note 10 - Lease Liability

Note 10 - Lease Liability	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Lease liability Aptose leases office space and lab space in San Diego, California. The lease for the office space expires on March 31, 2023 5 February 28, 2022. June 30, 2023 5 not Minimum payments, undiscounted, under our operating leases are as follows: Years ending December 31, 2021 $ 552 2022 464 2023 119 Thereafter - $ 1,135 To calculate the lease liability, the lease payments in the table above were discounted over the remaining term of the leases using the Company's incremental borrowing rate as at January 1, 2019 842, Year ended December 31, 2020 Year ended December 31, 2019 Weighted-average remaining term – operating leases (years) 2.1 3.3 Weighted-average discount rate – operating leases 5.40 % 5.43 % Lease liability, current portion 539 521 Lease liability, long term portion 535 1,011 Lease liability, total 1,074 1,532 Right-of-use assets obtained in exchange for new operating lease liabilities are as follows: Year ended December 31, 2020 Year ended December 31, 2019 Right-of-use assets recorded upon adoption of Topic 842, beginning of period - $ 1,570 Right-of-use assets obtained in exchange for new operating lease liabilities in the period $ 11 $ 267 Operating lease costs and operating cash flows from our operating leases are as follows: Year ended December 31, 2020 Year ended December 31, 2019 Operating lease cost $ 530 $ 551 Operating cash flows from operating leases $ 537 $ 471

Note 11 - Share Capital

Note 11 - Share Capital	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Share capital: The Company has authorized share capital of an unlimited number of common voting shares. (a) Equity issuances: (i) July/August 2020 On July 20, 2020 August 10, 2020, 11,854,472 $5.25 $62.236 $58.234 6% (ii) December 2019 On December 19, 2019, 18,543,750 $4.00 $74.175 $68.588 7% (iii) June 2019 On June 3, 2019, 11,500,000 $1.85 $21.275 $19.594 7% (iv) 2019 On May 7, 2019, 2019 $20 30 May 13, 2019, 171,428 2019 $360 May 7, 2019 December 16, 2019, 2019 1,800,000 $2.43 $4.37 (v) 2018 On May 30, 2018, 2018 $20 30 June 8, 2018, 170,261 2018 $600 January 1, 2019 May 24, 2019, 2018 5,502,433 $1.82 $10 May 24, 2019, $11.9 2018 May 24, 2019, 6,409,980, (vi) 2020 On May 5, 2020, 2020 2020 may, $75 December 31, 2020, not 2020 (vii) 2019 On May 24, 2019, may, $40 May 24, 2019 December 16, 2019, not (viii) 2018 On March 27, 2018, may, $30 January 1, 2019 May 24, 2019, 77,349 $2.37 $183 $178 3% May 24, 2019, $11.2 $10.9 (b) Loss per share: Loss per common share is calculated using the weighted average number of common shares outstanding and is presented in the table below: (in thousands) Year ended Year ended Net loss $ (55,238 ) $ (26,277 ) Weighted-average common shares – basic and diluted 81,837 50,160 Net loss per share – basic and diluted $ (0.67 ) $ (0.52 ) The effect of any potential exercise of the Company's stock options outstanding during the year has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based compensation: (a) Stock options Under the Company's stock option plan, options, rights and other entitlements may 17.5% 15.6 December 31, 2020. four 10 Stock option transactions for the years ended December 31, 2019 2020 Option numbers are in (000's) Weighted average Aggregate Options Weighted average remaining contractual Intrinsic Outstanding, December 31, 2018 4,489 3.11 Granted 2,160 2.00 Exercised (312 ) 2.32 Expired (67 ) 4.61 Forfeited (329 ) 2.36 Outstanding, December 31, 2019 5,941 $ 2.84 Granted 6,362 6.81 Exercised (235 ) 2.45 Forfeited (126 ) 4.50 Outstanding, December 31, 2020 11,942 4.97 7.9 $ 9,142,263 Exercisable, December 31, 2020 4,363 3.06 6.2 $ 6,470,708 Vested and expected to vest, December 31, 2020 10,804 4.86 7.8 $ 8,741,530 Aggregate intrinsic value represents the excess of the value of the closing stock price on the previous trading day of the respective balance sheet dates over the exercise price of the stock options. Total intrinsic value of options exercised was $850 2020 2019 $259 As of December 31, 2020, $9.52 1.83 The following table presents the weighted average assumptions that were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the year, and the resultant weighted average fair values: Year ended December 31, 2020 Year ended December 31, 2019 Risk-free interest rate 1.27 % 2.18 % Expected dividend yield - - Expected volatility 85.9 % 83.9 % Expected life of options (years) 5 5 Grant date fair value $ 4.59 $ 1.34 The Company uses historical data to estimate the expected dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. The following table presents the vesting terms of options granted in the period: Option numbers are in (000's) Year ended Year ended Number of options Number of options Cliff vesting after one year anniversary 300 335 3 year vesting (50%-25%-25%) 862 160 4 year vesting (50%-16 2/3%-16 2/3%-16 2/3%) 5,200 1,665 Total stock options granted in the period 6,362 2,160 (b) Restricted share units The Company has a stock incentive plan (SIP) pursuant to which the Board may one December 31, 2020 2019 Year ended, Year ended, Number (in thousands) Weighted average grant date fair value Number (in thousands) Weighted average grant date fair value Outstanding, beginning of year 40 $ 2.00 - $ - Granted 645 7.32 80 2.00 Redeemed (685 ) 7.01 (40 ) 2.00 Outstanding, end of year - $ - 40 $ 2.00 On March 10, 2020, 645,000 three May 5, 2020, three four July 10, 2020, 645,000 On June 3, 2019, 80,000 40,000 three one September 3, 2019, 50% 40,000 May 5, 2020, one one one July 2, 2020, 40,000 The grant date fair value of the March 10, 2020 June 3, 2019 (c) Share-based payment expense The Company recorded share-based payment expense related to stock options and RSUs as follows: Year ended Year ended Research and development $ 3,720 $ 474 General and administrative 17,718 1,822 Total $ 21,438 $ 2,296

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Related party transactions: The Company uses Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is a member of our Scientific Advisory Board and former Acting Chief Medical Officer of Aptose up to January 1, 2020 March 2015 During the comparative year ended December 31, 2019, $223

Note 14 - Collaborative Agreeme

Note 14 - Collaborative Agreements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Collaborative Agreements [Text Block]	14. Collaborative agreements: The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may Under the Company's license agreement with CrystalGenomics for rights to CG- 806, $16 2 $44 may not On June 13, 2018, 806 $6 2 $20 may not On March 7, 2018, 581, two $125

Note 15 - Income Taxes

Note 15 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	15. Income taxes: (a) Recent tax legislation In December 2017 January 1, 2018, 35% 21%, (b) Income taxes For the years ended December 31, 2019 2020, December 31, 2020 December 31, 2019 Loss attributed to US foreign operations $ (39,757 ) $ (20,470 ) Loss attributed to Canadian operations (15,481 ) (5,807 ) Income (loss) before income taxes $ (55,238 ) $ (26,277 ) (c) Tax rate reconciliation Major items causing the Company's income tax rate to differ from the statutory rate of approximately 26.5% December 31, 2019 26.5% Year ended Year ended Net loss $ (55,238 ) $ (26,277 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (14,638 ) $ (6,963 ) Non-deductible permanent differences 4,959 (1,305 ) Change in valuation allowance 10,383 12,146 Foreign tax rate differential (428 ) (286 ) Foreign exchange differences - - Prior year true-up adjustments (230 ) (3,563 ) Other (46 ) (29 ) $ - $ - (d) Significant components of deferred taxes The tax effects of temporary differences that give rise to significant portions of the unrecognized deferred tax assets are presented below: December 31, 2020 December 31, 2019 Net operating losses carried forward $ 37,362 $ 26,786 Research and development expenditures 5,032 5,031 Property, equipment, and other intangible assets 3,760 4,191 Research and development tax credits 3,597 3,685 Financing costs 2,336 2,010 Right-of-use assets 40 41 Total deferred tax assets 52,127 41,744 Valuation allowance (52,127 ) (41,744 ) Net deferred tax asset $ - $ - The valuation allowance at December 31, 2020 not not not not not not The Company has Canadian undeducted research and development expenditures, totaling $19.0 $3.6 2021, $0.9 2038. In addition, the Company has Canadian non-capital loss carryforwards of $135.2 not 2026. $0.7 not 2034. The Company files income tax returns with Canada and its provinces and territories. Generally, we are subject to routine examinations by the Canada Revenue Agency ("CRA"). Income tax returns filed with various provincial jurisdictions are generally open to examination for periods of four five The Company also files income tax returns for our U.S. operations and subsidiary with the U.S. federal and state tax jurisdictions. Generally, we are subject to routine examination by taxing authorities in the U.S. jurisdictions. There are presently no

Note 16 - Selected Quarterly Fi

Note 16 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Quarterly Financial Information [Text Block]	16. Selected quarterly financial data (unaudited): Selected financial data (unaudited) for the periods presented was as follows: March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Revenue $ - $ - $ - $ - Net loss (11,526 ) (15,750 ) (13,249 ) (14,713 ) Basic and diluted loss per common share (0.15 ) (0.21 ) (0.15 ) (0.17 ) March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 Revenue $ - $ - $ - $ - Net loss (5,506 ) (6,218 ) (6,844 ) (7,709 ) Basic and diluted loss per common share (0.14 ) (0.13 ) (0.12 ) (0.13 )

Note 17 - Subsequent Events

Note 17 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	17. Subsequent events Subsequent to the year end, the Company issued 2,746,750 $4.36. 50% one 16.67 three 430,000 50% one 25% two

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	(a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation.
Basis of Accounting, Policy [Policy Text Block]	(b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10
Use of Estimates, Policy [Policy Text Block]	(c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.
Lessee, Leases [Policy Text Block]	(d) Leases Effective January 1, 2019, No. 2016 02, 842 twelve Impact of adoption: As a result of adopting Topic 842, January 1, 2019, $1.570 $1.647 $78
Cash and Cash Equivalents, Policy [Policy Text Block]	(e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90
Investment, Policy [Policy Text Block]	(f) Investments: Investments consist of time deposits with original maturities greater than 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	(g) Concentration of risk: The Company is subject to credit risk from the Company's cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1
Property, Plant and Equipment, Policy [Policy Text Block]	(h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight-line basis as follows: Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate.
Research and Development Expense, Policy [Policy Text Block]	(i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed. The Company records expenses for research and development activities based on Management's estimates of services received and efforts expended pursuant to contracts with vendors that conduct research and development on Aptose's behalf. The financial terms vary from contract to contract and may
Fair Value Measurement, Policy [Policy Text Block]	(j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company's financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Share-based Payment Arrangement [Policy Text Block]	(k) Stock-based compensation: The Company has a stock-based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company's Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company's stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non-employees are measured at grant-date fair value of the equity instruments issued in accordance with FASB issued accounting standards update No 2018 07, 718. The Company has a stock incentive plan pursuant to which the Board may
Segment Reporting, Policy [Policy Text Block]	(l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company's Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one
Earnings Per Share, Policy [Policy Text Block]	(m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company's stock options and warrants in the computation of diluted loss per share has an anti-dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share.
Income Tax, Policy [Policy Text Block]	(n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2020 December 31, 2019, not not

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment, Useful Life [Table Text Block]	Office furniture (years) 5 Laboratory equipment (years) 5 Computer hardware (years) 3 Computer software (years) 3 Leasehold improvements Life of lease

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, December 31, 2020 2019 Prepaid research and development expenses $ 622 $ 451 Other prepaid expenses 1,932 574 $ 2,554 $ 1,025

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2020 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 177 $ 8 Computer hardware 170 99 71 Computer software 222 174 48 Office furniture 140 72 68 Leasehold improvements 184 118 66 $ 901 $ 640 $ 261 December 31, 2019 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 160 $ 25 Computer hardware 122 60 62 Computer software 222 128 94 Office furniture 116 51 65 Leasehold improvements 177 89 88 $ 822 $ 488 $ 334

Note 6 - Right of-use Assets,_2

Note 6 - Right of-use Assets, Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Right-of-use Assets [Table Text Block]	Year ended December 31, 2020 Year ended Right-of-use assets, beginning of year $ 1,837 $ 1,570 Additions to right-of-use assets 11 267 Right-of-use assets, end of year 1,848 1,837 Accumulated amortization (923 ) (461 ) Right-of use assets, NBV 925 1,376

Note 7 - Investments (Tables)

Note 7 - Investments (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Investment [Table Text Block]	December 31, 2020 Cost Unrealized gain/(loss) Market value United States Treasury Bills 5,000 - 5,000 5,000 - 5,000 December 31, 2019 Cost Unrealized gain Market value Guaranteed investment certificates, issued by a Canadian financial institution 12,008 18 12,026 Commercial notes 3,736 - 3,736 Canadian provincial promissory note 1,996 - 1,996 17,740 18 17,758

Note 8 - Fair Value Measureme_2

Note 8 - Fair Value Measurements and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	December 31, 2020 Level 1 Level 2 Level 3 Assets Money Market accounts $ 668 - $ 668 - Money Market Funds 44,000 - 44,000 - High interest savings accounts 48,397 $ - 48,397 - United States Treasury Bill 5,000 - 5,000 - Government of Canada Treasury Bill 23,999 - 23,999 - $ 122,064 $ - $ 122,064 $ - December 31, 2019 Level 1 Level 2 Level 3 Assets High interest savings account $ 2,989 $ - $ 2,989 - Commercial notes 6,235 - 6,235 - Canadian provincial promissory notes 5,493 - 5,493 - Guaranteed investment certificates, issued by a Canadian financial institution 81,243 - 81,243 - $ 95,960 $ - $ 95,960 $ -

Note 9 - Accrued Liabilities (T

Note 9 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2020 2019 Accrued personnel related costs $ 1,917 $ 1,739 Accrued research and development expenses 1,932 1,062 Other accrued expenses 253 257 $ 4,102 $ 3,058

Note 10 - Lease Liability (Tabl

Note 10 - Lease Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Years ending December 31, 2021 $ 552 2022 464 2023 119 Thereafter - $ 1,135
Lessee, Operating Lease Liability and Weighted Average [Table Text Block]	Year ended December 31, 2020 Year ended December 31, 2019 Weighted-average remaining term – operating leases (years) 2.1 3.3 Weighted-average discount rate – operating leases 5.40 % 5.43 % Lease liability, current portion 539 521 Lease liability, long term portion 535 1,011 Lease liability, total 1,074 1,532
Schedule of Right-of-use Asset Obtained in Exchange For Operating Lease Liability [Table Text Block]	Year ended December 31, 2020 Year ended December 31, 2019 Right-of-use assets recorded upon adoption of Topic 842, beginning of period - $ 1,570 Right-of-use assets obtained in exchange for new operating lease liabilities in the period $ 11 $ 267
Lease, Cost [Table Text Block]	Year ended December 31, 2020 Year ended December 31, 2019 Operating lease cost $ 530 $ 551 Operating cash flows from operating leases $ 537 $ 471

Note 11 - Share Capital (Tables

Note 11 - Share Capital (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	(in thousands) Year ended Year ended Net loss $ (55,238 ) $ (26,277 ) Weighted-average common shares – basic and diluted 81,837 50,160 Net loss per share – basic and diluted $ (0.67 ) $ (0.52 )

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Option numbers are in (000's) Weighted average Aggregate Options Weighted average remaining contractual Intrinsic Outstanding, December 31, 2018 4,489 3.11 Granted 2,160 2.00 Exercised (312 ) 2.32 Expired (67 ) 4.61 Forfeited (329 ) 2.36 Outstanding, December 31, 2019 5,941 $ 2.84 Granted 6,362 6.81 Exercised (235 ) 2.45 Forfeited (126 ) 4.50 Outstanding, December 31, 2020 11,942 4.97 7.9 $ 9,142,263 Exercisable, December 31, 2020 4,363 3.06 6.2 $ 6,470,708 Vested and expected to vest, December 31, 2020 10,804 4.86 7.8 $ 8,741,530
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31, 2020 Year ended December 31, 2019 Risk-free interest rate 1.27 % 2.18 % Expected dividend yield - - Expected volatility 85.9 % 83.9 % Expected life of options (years) 5 5 Grant date fair value $ 4.59 $ 1.34
Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]	Option numbers are in (000's) Year ended Year ended Number of options Number of options Cliff vesting after one year anniversary 300 335 3 year vesting (50%-25%-25%) 862 160 4 year vesting (50%-16 2/3%-16 2/3%-16 2/3%) 5,200 1,665 Total stock options granted in the period 6,362 2,160
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year ended, Year ended, Number (in thousands) Weighted average grant date fair value Number (in thousands) Weighted average grant date fair value Outstanding, beginning of year 40 $ 2.00 - $ - Granted 645 7.32 80 2.00 Redeemed (685 ) 7.01 (40 ) 2.00 Outstanding, end of year - $ - 40 $ 2.00
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended Year ended Research and development $ 3,720 $ 474 General and administrative 17,718 1,822 Total $ 21,438 $ 2,296

Note 15 - Income Taxes (Tables)

Note 15 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	December 31, 2020 December 31, 2019 Loss attributed to US foreign operations $ (39,757 ) $ (20,470 ) Loss attributed to Canadian operations (15,481 ) (5,807 ) Income (loss) before income taxes $ (55,238 ) $ (26,277 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended Year ended Net loss $ (55,238 ) $ (26,277 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (14,638 ) $ (6,963 ) Non-deductible permanent differences 4,959 (1,305 ) Change in valuation allowance 10,383 12,146 Foreign tax rate differential (428 ) (286 ) Foreign exchange differences - - Prior year true-up adjustments (230 ) (3,563 ) Other (46 ) (29 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2020 December 31, 2019 Net operating losses carried forward $ 37,362 $ 26,786 Research and development expenditures 5,032 5,031 Property, equipment, and other intangible assets 3,760 4,191 Research and development tax credits 3,597 3,685 Financing costs 2,336 2,010 Right-of-use assets 40 41 Total deferred tax assets 52,127 41,744 Valuation allowance (52,127 ) (41,744 ) Net deferred tax asset $ - $ -

Note 16 - Selected Quarterly _2

Note 16 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Quarterly Financial Information [Table Text Block]	March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Revenue $ - $ - $ - $ - Net loss (11,526 ) (15,750 ) (13,249 ) (14,713 ) Basic and diluted loss per common share (0.15 ) (0.21 ) (0.15 ) (0.17 ) March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 Revenue $ - $ - $ - $ - Net loss (5,506 ) (6,218 ) (6,844 ) (7,709 ) Basic and diluted loss per common share (0.14 ) (0.13 ) (0.12 ) (0.13 )

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 925	$ 1,837	$ 1,376	$ 1,570
Operating Lease, Liability, Total	$ 1,074		1,532	$ 1,647
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Number of Operating Segments	1
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 1,570
Landlord Inducements	$ 78

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Property, Plant and Equipment Useful Life (Details)	12 Months Ended
	Dec. 31, 2020
Furniture and Fixtures [Member]
Property, plant and equipment, useful life (Year)	5 years
Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	5 years
Computer Equipment [Member]
Property, plant and equipment, useful life (Year)	3 years
Software and Software Development Costs [Member]
Property, plant and equipment, useful life (Year)	3 years
Leasehold Improvements [Member]
Property, plant and equipment, estimated useful life	Life of lease

Note 3 - Cash and Cash Equiva_2

Note 3 - Cash and Cash Equivalents (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cash, Ending Balance	$ 329	$ 1,640
Cash Equivalents, at Carrying Value, Total	$ 117,064	$ 78,202

Note 4 - Prepaid Expenses - Pre

Note 4 - Prepaid Expenses - Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Prepaid research and development expenses	$ 622	$ 451
Other prepaid expenses	1,932	574
Prepaid Expense, Current, Total	$ 2,554	$ 1,025

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, plant and equipment, gross	$ 901	$ 822
Accumulated depreciation	640	488
Property, plant and equipment, net	261	334
Laboratory Equipment [Member]
Property, plant and equipment, gross	185	185
Accumulated depreciation	177	160
Property, plant and equipment, net	8	25
Computer Equipment [Member]
Property, plant and equipment, gross	170	122
Accumulated depreciation	99	60
Property, plant and equipment, net	71	62
Software and Software Development Costs [Member]
Property, plant and equipment, gross	222	222
Accumulated depreciation	174	128
Property, plant and equipment, net	48	94
Furniture and Fixtures [Member]
Property, plant and equipment, gross	140	116
Accumulated depreciation	72	51
Property, plant and equipment, net	68	65
Leasehold Improvements [Member]
Property, plant and equipment, gross	184	177
Accumulated depreciation	118	89
Property, plant and equipment, net	$ 66	$ 88

Note 6 - Right of-use Assets,_3

Note 6 - Right of-use Assets, Operating Leases - Schedule of Right-of-use Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2020	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 925	$ 1,376	$ 1,837	$ 1,570
Additions to right-of-use assets	11	267
Right-of-use assets, end of year	1,848	1,837
Accumulated amortization	(923)	(461)
Right-of use assets, NBV	$ 925	$ 1,376	$ 1,837	$ 1,570

Note 7 - Investments - Investme

Note 7 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Investment, Cost	$ 5,000	$ 17,740
Investment, Unrealized gain/(loss)		18
Investment, Market value	5,000	17,758
US Treasury Securities [Member]
Investment, Cost	5,000
Investment, Unrealized gain/(loss)
Investment, Market value	$ 5,000
Investments [Member]
Investment, Cost		12,008
Investment, Unrealized gain/(loss)		18
Investment, Market value		12,026
Corporate Debt Securities [Member]
Investment, Cost		3,736
Investment, Unrealized gain/(loss)
Investment, Market value		3,736
Canadian Provincial Promissory Notes [Member]
Investment, Cost		1,996
Investment, Unrealized gain/(loss)
Investment, Market value		$ 1,996

Note 8 - Fair Value Measureme_3

Note 8 - Fair Value Measurements and Financial Instruments - Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets, fair value	$ 122,064
Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	122,064
Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Fair Value, Recurring [Member]
Assets, fair value		$ 95,960
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		95,960
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Money Market Accounts [Member]
Assets, fair value	668
Money Market Accounts [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Money Market Accounts [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	668
Money Market Accounts [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Bank Time Deposits [Member]
Assets, fair value	48,397
Bank Time Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	48,397
Bank Time Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Bank Time Deposits [Member] | Fair Value, Recurring [Member]
Assets, fair value		2,989
Bank Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Bank Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		2,989
Bank Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Money Market Funds [Member]
Assets, fair value	44,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	44,000
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Assets, fair value		6,235
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		6,235
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Canadian Provincial Promissory Notes [Member] | Fair Value, Recurring [Member]
Assets, fair value		5,493
Canadian Provincial Promissory Notes [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Canadian Provincial Promissory Notes [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		5,493
Canadian Provincial Promissory Notes [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
US Treasury Securities [Member]
Assets, fair value	5,000
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	5,000
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Investments [Member] | Fair Value, Recurring [Member]
Assets, fair value		81,243
Investments [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Investments [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		81,243
Investments [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Canadian Treasury Securities [Member]
Assets, fair value	23,999
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	23,999
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value

Note 9 - Accrued Liabilities -

Note 9 - Accrued Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued personnel related costs	$ 1,917	$ 1,739
Accrued research and development expenses	1,932	1,062
Other accrued expenses	253	257
Accrued Liabilities, Current, Total	$ 4,102	$ 3,058

Note 10 - Lease Liability (Deta

Note 10 - Lease Liability (Details Textual)	Dec. 31, 2020
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 10 - Lease Liability - Sch

Note 10 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
2021	$ 552
2022	464
2023	119
Thereafter
Lessee, Operating Lease, Liability, to be Paid, Total	$ 1,135

Note 10 - Lease Liability - Lea

Note 10 - Lease Liability - Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Weighted-average remaining term – operating leases (years) (Year)	2 years 36 days	3 years 109 days
Weighted-average discount rate – operating leases	5.40%	5.43%
Lease liability, current portion	$ 539	$ 521
Lease liability, long term portion	535	1,011
Operating Lease, Liability, Total	$ 1,074	$ 1,532	$ 1,647

Note 10 - Lease Liability - S_2

Note 10 - Lease Liability - Schedule of Right-of-use Asset Obtained in Exchange for Operating Lease Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2020	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 925	$ 1,376	$ 1,837	$ 1,570
Right-of-use assets obtained in exchange for new operating lease liabilities in the period	11	267
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		1,570
Right-of-use assets obtained in exchange for new operating lease liabilities in the period	$ 11	$ 267

Note 10 - Lease Liability - Ope

Note 10 - Lease Liability - Operating Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating lease cost	$ 530	$ 551
Operating cash flows from operating leases	$ 537	$ 471

Note 11 - Share Capital (Detail

Note 11 - Share Capital (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 10, 2020	Dec. 19, 2019	Jun. 03, 2019	May 24, 2019	May 23, 2019	May 13, 2019	Jun. 08, 2018	May 23, 2019	Dec. 16, 2019	Dec. 31, 2020	Dec. 31, 2019	May 05, 2020	May 07, 2019	May 30, 2018	Mar. 27, 2018
July 2020 Confidentially Marketed Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	11,854,472
Shares Issued, Price Per Share (in dollars per share)	$ 5.25
Proceeds from Issuance of Common Stock, Gross	$ 62,236
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs	$ 58,234
Stock Issuance, Percent of Cash Commission to Broker	6.00%
December 2019 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		18,543,750
Shares Issued, Price Per Share (in dollars per share)		$ 4
Proceeds from Issuance of Common Stock, Gross		$ 74,175
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs		$ 68,588
Stock Issuance, Percent of Cash Commission to Broker		7.00%
Stock Issued During Period, Value, New Issues											$ 68,588
Proceeds from Issuance of Common Stock											68,883
June 2019 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			11,500,000
Shares Issued, Price Per Share (in dollars per share)			$ 1.85
Proceeds from Issuance of Common Stock, Gross			$ 21,275
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs			$ 19,594
Stock Issuance, Percent of Cash Commission to Broker			7.00%
Stock Issued During Period, Value, New Issues											19,594
Proceeds from Issuance of Common Stock											19,736
The 2019 Share Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						171,428			1,800,000
Shares Issued, Price Per Share (in dollars per share)									$ 2.43
Stock Issuance Program, Authorized Amount													$ 20,000
Stock Issued During Period, Value, New Issues						$ 360					4,730
Proceeds from Issuance of Common Stock									$ 4,370		4,370
The 2018 Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				6,409,980			170,261			5,502,433
Shares Issued, Price Per Share (in dollars per share)										$ 1.82
Proceeds from Issuance of Common Stock, Gross							$ 11,900			$ 10,000
Stock Issuance Program, Authorized Amount														$ 20,000
Stock Issued During Period, Value, New Issues							$ 600				10,000
Proceeds from Issuance of Common Stock											10,000
The 2019 ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)										0
Stock Issuance Program, Authorized Amount				$ 40,000								$ 75,000
The 2018 ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				77,349
Shares Issued, Price Per Share (in dollars per share)				$ 2.37
Proceeds from Issuance of Common Stock, Gross				$ 11,200				$ 183
Stock Issuance, Percent of Cash Commission to Broker				3.00%
Stock Issuance Program, Authorized Amount															$ 30,000
Stock Issued During Period, Value, New Issues											178
Proceeds from Issuance of Common Stock				$ 10,900	$ 178						$ 178

Note 11 - Share Capital - Loss

Note 11 - Share Capital - Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (55,238)	$ (26,277)
Weighted-average common shares – basic and diluted (in shares)									81,837	50,160
Net loss per share – basic and diluted (in dollars per share)	$ (0.17)	$ (0.15)	$ (0.21)	$ (0.15)	$ (0.13)	$ (0.12)	$ (0.13)	$ (0.14)	$ (0.67)	$ (0.52)

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	Jul. 10, 2020	Jul. 02, 2020	May 05, 2020	Mar. 10, 2020	Sep. 03, 2019	Jun. 03, 2019	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Subscription Rate							17.50%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares (in shares)							15,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)							4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value							$ 850	$ 259
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 9,520
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							1 year 302 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			120 days	90 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	645,000	40,000		645,000		80,000	645,000	80,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)					40,000		685,000	40,000
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						90 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						40,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					50.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			1 year 30 days			1 year

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Stock Option Transactions (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Outstanding, options (in shares)	5,941	4,489
Outstanding, weighted average exercise price (in dollars per share)	$ 2.84	$ 3.11
Granted, options (in shares)	6,362	2,160
Granted, weighted average exercise price (in dollars per share)	$ 6.81	$ 2
Exercised, options (in shares)	(235)	(312)
Exercised, weighted average exercise price (in dollars per share)	$ 2.45	$ 2.32
Expired, options (in shares)		(67)
Expired, weighted average exercise price (in dollars per share)		$ 4.61
Forfeited, options (in shares)	(126)	(329)
Forfeited, weighted average exercise price (in dollars per share)	$ 4.50	$ 2.36
Outstanding, options (in shares)	11,942	5,941
Outstanding, weighted average exercise price (in dollars per share)	$ 4.97	$ 2.84
Outstanding, weighted average remaining contractual life (Year)	7 years 328 days
Outstanding, aggregate intrinsic value	$ 9,142,263
Exercisable, options (in shares)	4,363
Exercisable, weighted average exercise price (in dollars per share)	$ 3.06
Exercisable, weighted average remaining contractual life (Year)	6 years 73 days
Exercisable, aggregate intrinsic value	$ 6,470,708
Vested and expected to vest, options (in shares)	10,804
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 4.86
Vested and expected to vest, weighted average remaining contractual life (Year)	7 years 292 days
Vested and expected to vest, aggregate intrinsic value	$ 8,741,530

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Risk-free interest rate	1.27%	2.18%
Expected dividend yield
Expected volatility	85.90%	83.90%
Expected life of options (Year)	5 years	5 years
Grant date fair value (in dollars per share)	$ 4.59	$ 1.34

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock options granted in the period (in shares)	6,362	2,160
Options with Cliff Vesting After One Year Anniversary [Member]
Stock options granted in the period (in shares)	300	335
Options with Three Year Vesting [Member]
Stock options granted in the period (in shares)	862	160
Options with Four Year Vesting [Member]
Stock options granted in the period (in shares)	5,200	1,665

Note 12 - Stock-based Compens_7

Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche One [Member]
Vesting percentage	50.00%	50.00%
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Vesting percentage	25.00%	25.00%
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Vesting percentage	25.00%	25.00%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche One [Member]
Vesting percentage	50.00%	50.00%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Vesting percentage	16.67%	16.67%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Vesting percentage	16.67%	16.67%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Four [Member]
Vesting percentage	16.67%	16.67%

Note 12 - Stock-based Compens_8

Note 12 - Stock-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	Jul. 10, 2020	Jul. 02, 2020	Mar. 10, 2020	Sep. 03, 2019	Jun. 03, 2019	Dec. 31, 2020	Dec. 31, 2019
Outstanding, beginning of year (in shares)						40,000
Outstanding, beginning of year (in dollars per share)						$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	645,000	40,000	645,000		80,000	645,000	80,000
Granted, weighted average grant date fair value (in dollars per share)						$ 7.32	$ 2
Redeemed (in shares)				(40,000)		(685,000)	(40,000)
Vested, end of period, weighted average grant date fair value (in dollars per share)						$ 7.01	$ 2
Outstanding, end of year (in shares)							40,000
Outstanding, end of year (in dollars per share)							$ 2

Note 12 - Stock-based Compens_9

Note 12 - Stock-based Compensation - Share-based Payment Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based payment expense	$ 21,438	$ 2,296
Research and Development Expense [Member]
Share-based payment expense	3,720	474
General and Administrative Expense [Member]
Share-based payment expense	$ 17,718	$ 1,822

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Moores Cancer Center at University of California San Diego [Member] | Research and Development Expense, Related Party [Member]
Related Party Transaction, Amounts of Transaction	$ 223

Note 14 - Collaborative Agree_2

Note 14 - Collaborative Agreements (Details Textual) - USD ($) $ in Millions	Dec. 31, 2020	Jun. 13, 2018	Mar. 07, 2018
CrystalGenomics [Member]
Collaborative Agreement, Milestone Payment	$ 16
Collaborative Agreement, Regulatory Milestone	$ 44
CrystalGenomics [Member] | Exclusive License to CG806 in China, Development Milestones [Member]
Collaborative Agreement, Regulatory Milestone		$ 6
CrystalGenomics [Member] | Exclusive License to CG806 in China, Regulatory Milestones [Member]
Collaborative Agreement, Regulatory Milestone		$ 20
Ohm Oncology [Member]
Collaborative Agreements, Potential Additional Milestone Payments Receivable			$ 125

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	26.50%	26.50%
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards, Total	$ 135.2
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	0.7
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	19
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount	0.9
Investment Tax Credit Carryforward [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Tax Credit Carryforward, Amount	$ 3.6

Note 15 - Income Taxes - Net Lo

Note 15 - Income Taxes - Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Loss attributed to US foreign operations									$ (39,757)	$ (20,470)
Loss attributed to Canadian operations									(15,481)	(5,807)
Net loss	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (55,238)	$ (26,277)

Note 15 - Income Taxes - Provis

Note 15 - Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (55,238)	$ (26,277)
Statutory Canadian corporate tax rate									26.50%	26.50%
Computed expected tax recovery									$ (14,638)	$ (6,963)
Non-deductible permanent differences									4,959	(1,305)
Change in valuation allowance									10,383	12,146
Foreign tax rate differential									(428)	(286)
Foreign exchange differences
Prior year true-up adjustments									(230)	(3,563)
Other									$ (46)	$ (29)

Note 15 - Income Taxes - Deferr

Note 15 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Net operating losses carried forward	$ 37,362	$ 26,786
Research and development expenditures	5,032	5,031
Property, equipment, and other intangible assets	3,760	4,191
Research and development tax credits	3,597	3,685
Financing costs	2,336	2,010
Right-of-use assets	40	41
Total deferred tax assets	52,127	41,744
Valuation allowance	(52,127)	(41,744)
Net deferred tax asset

Note 16 - Selected Quarterly _3

Note 16 - Selected Quarterly Financial Data (Unaudited) - Quarterly Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenue
Net loss	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (7,709)	$ (6,844)	$ (6,218)	$ (5,506)	$ (55,238)	$ (26,277)
Basic and diluted loss per common share (in dollars per share)	$ (0.17)	$ (0.15)	$ (0.21)	$ (0.15)	$ (0.13)	$ (0.12)	$ (0.13)	$ (0.14)	$ (0.67)	$ (0.52)

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - $ / shares	Jan. 01, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		6,362,000	2,160,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 6.81	$ 2
Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		5,200,000	1,665,000
Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		862,000	160,000
Share-based Payment Arrangement, Tranche One [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%	50.00%
Share-based Payment Arrangement, Tranche One [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%	50.00%
Share-based Payment Arrangement, Tranche Two [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Two [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Payment Arrangement, Tranche Three [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Three [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Payment Arrangement, Tranche Four [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	2,746,750
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 4.36
Subsequent Event [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	430,000
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche One [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche One [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Four [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%